Literature DB >> 23800756

Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab.

Alessandro Allegra1, Giacomo Oteri2, Andrea Alonci3, Francesco Bacci4, Giuseppa Penna3, Viviana Minardi3, Valerio Maisano3, Caterina Musolino3.   

Abstract

POEMS syndrome, is a rare condition characterized by polyneuropathy, organomegaly, endocrinopathy, monoclonal proteinaemia, and skin lesions. We report a rare case of a patient affected by Waldenström macroglobulinemia, who developed POEMS syndrome and who presented at the time of diagnosis with oral manifestations of the lymphoma and an osteonecrosis of the jaw (ONJ) after rituximab treatment. Although the etiology of ONJ is not known, it is likely that several factors are at play, including endothelial cell damage, decreased angiogenesis, and microvascular compromise. Our patient was treated with rituximab for a long period, and recent studies have demonstrated the possibility that rituximab, a monoclonal antibody directed against the CD20 can exert part of its anti-tumor action, through its action on angiogenesis. Although our report does not allow identification of rituximab as a new risk factor for the onset of the ONJ, further studies seem necessary to exclude a role of the antibody in the alterations of angiogenesis that could lead to the development of the syndrome after rituximab treatment.
Copyright © 2013 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bevacizumab; Oral manifestation; Osteonecrosis of the jaw; POEMS syndrome; Rituximab; Waldenström macroglobulinemia

Mesh:

Substances:

Year:  2013        PMID: 23800756     DOI: 10.1016/j.jcms.2013.05.014

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  6 in total

Review 1.  Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review.

Authors:  Mampei Kawahara; Shinichiro Kuroshima; Takashi Sawase
Journal:  Int J Implant Dent       Date:  2021-05-14

2.  Adalimumab: Another Medication Related to Osteonecrosis of the Jaws?

Authors:  Andrea Cassoni; Umberto Romeo; Valentina Terenzi; Marco Della Monaca; Oriana Rajabtork Zadeh; Ingrid Raponi; Maria Teresa Fadda; Antonella Polimeni; Valentino Valentini
Journal:  Case Rep Dent       Date:  2016-03-21

3.  A Case of Osteonecrosis of the Jaw in a Patient with Crohn's Disease Treated with Infliximab.

Authors:  Gianfranco Favia; Angela Tempesta; Luisa Limongelli; Vito Crincoli; Florenzo Iannone; Giovanni Lapadula; Eugenio Maiorano
Journal:  Am J Case Rep       Date:  2017-12-19

4.  Altered Long Noncoding RNA Expression Profile in Multiple Myeloma Patients with Bisphosphonate-Induced Osteonecrosis of the Jaw.

Authors:  Alessandro Allegra; Manuela Mania; Angela D'Ascola; Giacomo Oteri; Enrico Nastro Siniscalchi; Angela Avenoso; Vanessa Innao; Michele Scuruchi; Andrea Gaetano Allegra; Caterina Musolino; Salvatore Campo
Journal:  Biomed Res Int       Date:  2020-07-02       Impact factor: 3.411

5.  Osteoradionecrosis of the jaw in a patient with lymphoma treated with rituximab and concomitant involved field radiation therapy.

Authors:  Jesus D Gonzalez-Lugo; Rafi Kabarriti; Ioannis Mantzaris
Journal:  Adv Radiat Oncol       Date:  2018-06-04

Review 6.  Review and update on drugs related to the development of osteonecrosis of the jaw.

Authors:  A Eguia; L Bagán-Debón; F Cardona
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2020-01-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.